Paroxetine, Panorama and user reporting of ADRs: Consumer intelligence matters in clinical practice and post-marketing drug surveillance

International Journal of Risk and Safety in Medicine

Volumn 15, Issue 4/3, 2002, Pages 161-169

  Medawar, Charles ^a,d   Herxheimer, Andrew ^b   Bell, Andrew ^c   Jofre, Shelley ^c  

^a Social Audit Ltd   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BBC RESEARCH AND DEVELOPMENT   (United Kingdom)

^d Social Audit Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE;

ARTICLE; BEHAVIOR DISORDER; CLINICAL PRACTICE; CONSUMER; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; E-MAIL; HUMAN; INTERNET; MOOD DISORDER; SUICIDAL BEHAVIOR; SUICIDE; TELEVISION; WITHDRAWAL SYNDROME;

EID: 0037657836     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. C. Medawar, The Antidepressant Web - Marketing depression and making medicines work, Int. J. Risk & Safety in Medicine 10 (1997), 75-126 and www.socialaudit.org.uk (1998-2003).
2. www.socialaudit.org.uk/disc560_toc.htm.
3. www.bbc.co.uk/panorama.
4. M.H. Teicher, C.A. Glod and J.O. Cole, Antidepressant drugs and the emergence of suicidal tendencies, Drug Safety 8(3) (1993), 186-212.
5. S. Boseley, Murder, suicide. A bitter aftertaste for the 'wonder' depression drug, The Guardian (11 June 2001).
6. J.F. Rosenbaum, M. Fava, S.L. Hoog, R.C. Ascroft and W.B. Krebs, Selective serotonin reuptake inhibitor discontinuation syndrome: A randomised clinical trial, Biol Psychiatry 44 (1998), 77-87.
7. K. Demyttenaere, P. Enzlin, W. Dewe, B. Boulanger, J. De Bie, W. De Troyer and P. Mesters, Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events, J. Clin. Psychiatry 62(Suppl. 22) (2001), 30-33.
8. A.H. Young and A. Currie, Physicians' knowledge of antidepressant withdrawal effects: a survey, J. Clin. Psychiatry 58(Suppl. 7) (1997), 28-30.
9. D.W. Black, R. Wesner and J. Gabel, The abrupt discontinuation of fluvoxamine in patients with panic disorder, J. Clin. Psychiatry 54(4), (1993), 146-149.
10. P. Haddad and M. Qureshi, Misdiagnosis of antidepressant discontinuation symptoms, Acta Psychiatr. Scand. 102(6) (2000), 466-468.
11. J.S. Price, P.C. Waller, S.M. Wood and A.V.P. Mackay, A comparison of the post-marketing safety of four selective serotonin reuptake inhibitors including the investigation of symptoms occurring on withdrawal, Br. J. Clin. Pharmacol. 42 (1996), 757-763.
12. World Health Organisation (Anon), Selective serotonin re-uptake inhibitors and withdrawal reactions, WHO Drug Information 12(3) (1998), 136-138.
13. Anon, GSK's Paxil Ad is 'Acceptable': FDA, deposition filed at www.fdaweb.com, dated 17 September 2002.
14. Expert Committee on Drug Dependence, Terminology in reporting abuse-related adverse drug reactions, paper tabled at 33rd meeting of ECDD, 17-20 September 2002 (Geneva: World Health Organisation, in press).
15. MCA, personal communication to CM, 3 July 2002. See letter and attachment at http://www.socialaudit.org.uk/43800046.htm.
16. Medicines Control Agency, MCA response to 'Panorama' programme on Seroxat, posted 11 October 2002 at mca.gov.uk.
17. M.N.G. Dukes, ed., Consensus Document adopted at the First International Conference on Consumer Reports on Medicines (Sigtuna, Sweden: KILEN, September 29-October 1, 2000). Available at http://www.kilen.org/indexe.htm.
18. N. Jarernsiripornkul, J. Krska, P.A.G. Capps et al., Patient reporting of potential adverse drug reactions: a methodological study, British Journal of Clinical Pharmacology 53(3) (2002), 318-325.
19. N. Blau, Time to let the patient speak, BMJ 298(6665) (1989), 39.